Hamel Associates’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.27M | Sell |
20,068
-60
| -0.3% | -$20.5K | 2% | 17 |
|
|
2026
Q1 | $7.08M | Sell |
20,128
-75
| -0.4% | -$26.7K | 2.02% | 18 |
|
|
2025
Q4 | $6.61M | Sell |
20,203
-169
| -0.8% | -$53.6K | 1.99% | 18 |
|
|
2025
Q3 | $5.75M | Buy |
20,372
+740
| +4% | +$215K | 1.77% | 22 |
|
|
2025
Q2 | $5.48M | Buy |
19,632
+1,861
| +10% | +$527K | 1.86% | 24 |
|
|
2025
Q1 | $5.54M | Buy |
17,771
+1,025
| +6% | +$303K | 1.88% | 22 |
|
|
2024
Q4 | $4.36M | Sell |
16,746
-248
| -1% | -$73.6K | 1.4% | 29 |
|
|
2024
Q3 | $5.48M | Sell |
16,994
-101
| -0.6% | -$33K | 1.67% | 26 |
|
|
2024
Q2 | $5.34M | Sell |
17,095
-3
| -0% | -$881 | 1.68% | 27 |
|
|
2024
Q1 | $4.86M | Hold |
17,098
| – | – | 1.56% | 27 |
|
|
2023
Q4 | $4.92M | Buy |
17,098
+365
| +2% | +$99.5K | 1.74% | 25 |
|
|
2023
Q3 | $4.5M | Buy |
16,733
+215
| +1% | +$53.7K | 1.64% | 25 |
|
|
2023
Q2 | $3.67M | Buy |
16,518
+3,012
| +22% | +$699K | 1.28% | 33 |
|
|
2023
Q1 | $3.27M | Buy |
13,506
+132
| +1% | +$32.4K | 1.13% | 35 |
|
|
2022
Q4 | $3.51M | Hold |
13,374
| – | – | 1.22% | 36 |
|
|
2022
Q3 | $3.01M | Sell |
13,374
-175
| -1% | -$42.4K | 1.19% | 35 |
|
|
2022
Q2 | $3.3M | Sell |
13,549
-60
| -0.4% | -$14.7K | 1.3% | 30 |
|
|
2022
Q1 | $3.29M | Buy |
13,609
+489
| +4% | +$112K | 1.17% | 35 |
|
|
2021
Q4 | $2.95M | Buy |
13,120
+2,075
| +19% | +$438K | 1.06% | 33 |
|
|
2021
Q3 | $2.35M | Buy |
11,045
+960
| +10% | +$221K | 0.92% | 43 |
|
|
2021
Q2 | $2.46M | Sell |
10,085
-250
| -2% | -$61.5K | 0.94% | 42 |
|
|
2021
Q1 | $2.57M | Buy |
10,335
+560
| +6% | +$134K | 0.99% | 38 |
|
|
2020
Q4 | $2.25M | Sell |
9,775
-25
| -0.3% | -$5.76K | 0.92% | 38 |
|
|
2020
Q3 | $2.49M | Hold |
9,800
| – | – | 1.1% | 34 |
|
|
2020
Q2 | $2.31M | Hold |
9,800
| – | – | 1.11% | 34 |
|
|
2020
Q1 | $1.99M | Buy |
9,800
+325
| +3% | +$71K | 1.05% | 35 |
|
|
2019
Q4 | $2.28M | Hold |
9,475
| – | – | 0.94% | 40 |
|
|
2019
Q3 | $1.83M | Hold |
9,475
| – | – | 0.78% | 42 |
|
|
2019
Q2 | $1.75M | Buy |
9,475
+2,300
| +32% | +$412K | 0.77% | 42 |
|
|
2019
Q1 | $1.36M | Buy |
7,175
+2,950
| +70% | +$563K | 0.61% | 45 |
|
|
2018
Q4 | $822K | Buy |
4,225
+50
| +1% | +$9.76K | 0.41% | 59 |
|
|
2018
Q3 | $865K | Hold |
4,175
| – | – | 0.37% | 65 |
|
|
2018
Q2 | $771K | Sell |
4,175
-125
| -3% | -$22.1K | 0.35% | 64 |
|
|
2018
Q1 | $733 | Hold |
4,300
| – | – | 0.05% | 61 |
|
|
2017
Q4 | $748K | Hold |
4,300
| – | – | 0.35% | 52 |
|
|
2017
Q3 | $802K | Hold |
4,300
| – | – | 0.39% | 54 |
|
|
2017
Q2 | $741K | Buy |
4,300
+250
| +6% | +$40.7K | 0.37% | 52 |
|
|
2017
Q1 | $664K | Sell |
4,050
-900
| -18% | -$150K | 0.34% | 54 |
|
|
2016
Q4 | $723K | Buy |
4,950
+475
| +11% | +$71.5K | 0.37% | 53 |
|
|
2016
Q3 | $746K | Buy |
4,475
+250
| +6% | +$42.3K | 0.39% | 52 |
|
|
2016
Q2 | $643K | Buy |
+4,225
| New | +$657K | 0.33% | 59 |
|
|
2014
Q4 | – | Sell |
-1,600
| Closed | -$225K | – | 93 |
|
|
2014
Q3 | $225K | Buy |
+1,600
| New | +$209K | 0.15% | 90 |
|
Other funds holding AMGN
Hamel Associates's AMGN Position: Q2 2026 in Review
Hamel Associates reduced its Amgen (AMGN) stake by 0.3% in Q2 2026, selling an estimated $20.5K and leaving 20,068 shares worth $7.27M. The position accounts for 2% of the portfolio, ranked #17.
Hamel Associates first reported a position in AMGN in Q3 2014 and has held it in 42 quarters since. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.
- Hamel Associates held 20,068 shares of Amgen worth $7.27M as of Q2 2026.
- Hamel Associates sold 60 Amgen shares in Q2 2026, an estimated $20.5K.
- Amgen made up 2% of Hamel Associates's portfolio in Q2 2026, its #17 holding.
- Hamel Associates first reported a position in Amgen in Q3 2014 and has held it in 42 quarters since.
- 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.
Based on Hamel Associates's 13F filing for Q2 2026, filed 27 Jul 2026.